View ValuationTempo Scan Pacific 将来の成長Future 基準チェック /06現在、 Tempo Scan Pacificの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 14PT Tempo Scan Pacific Tbk, Annual General Meeting, Jun 05, 2026PT Tempo Scan Pacific Tbk, Annual General Meeting, Jun 05, 2026. Location: tempo scan tower, lt.16, jl. h. r. rasuna said kav, jakarta selatan kota adm. jakarta selatan dki., . jakarta indonesia, jakarta IndonesiaReported Earnings • May 05First quarter 2026 earnings released: EPS: Rp78.00 (vs Rp91.00 in 1Q 2025)First quarter 2026 results: EPS: Rp78.00 (down from Rp91.00 in 1Q 2025). Revenue: Rp3.41t (up 4.2% from 1Q 2025). Net income: Rp351.8b (down 14% from 1Q 2025). Profit margin: 10% (down from 13% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 01Full year 2025 earnings released: EPS: Rp312 (vs Rp321 in FY 2024)Full year 2025 results: EPS: Rp312 (down from Rp321 in FY 2024). Revenue: Rp14t (up 2.6% from FY 2024). Net income: Rp1.41t (down 2.8% from FY 2024). Profit margin: 10.0% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 04Third quarter 2025 earnings released: EPS: Rp95.94 (vs Rp58.00 in 3Q 2024)Third quarter 2025 results: EPS: Rp95.94 (up from Rp58.00 in 3Q 2024). Revenue: Rp3.54t (up 4.8% from 3Q 2024). Net income: Rp434.1b (up 66% from 3Q 2024). Profit margin: 12% (up from 7.8% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Nov 03Upcoming dividend of Rp100.00 per shareEligible shareholders must have bought the stock before 10 November 2025. Payment date: 25 November 2025. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Indonesian dividend payers (5.3%). Higher than average of industry peers (2.8%).Board Change • Oct 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 10 non-independent directors. Independent Commissioner Suparni Setiono was the last independent director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 16PT Tempo Scan Pacific Tbk, Annual General Meeting, May 23, 2025PT Tempo Scan Pacific Tbk, Annual General Meeting, May 23, 2025. Location: meeting both physically and eletronically, jakarta IndonesiaReported Earnings • Nov 01Third quarter 2024 earnings released: EPS: Rp58.00 (vs Rp57.12 in 3Q 2023)Third quarter 2024 results: EPS: Rp58.00 (up from Rp57.12 in 3Q 2023). Revenue: Rp3.37t (up 2.9% from 3Q 2023). Net income: Rp261.7b (flat on 3Q 2023). Profit margin: 7.8% (down from 7.9% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to Rp2,800, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 135% over the past three years.Reported Earnings • Aug 01Second quarter 2024 earnings released: EPS: Rp92.01 (vs Rp27.67 in 2Q 2023)Second quarter 2024 results: EPS: Rp92.01 (up from Rp27.67 in 2Q 2023). Revenue: Rp3.34t (up 2.5% from 2Q 2023). Net income: Rp413.6b (up 233% from 2Q 2023). Profit margin: 12% (up from 3.8% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 16% per year.Buy Or Sell Opportunity • May 21Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at Rp2,020. The fair value is estimated to be Rp2,541, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 18%.Reported Earnings • May 02First quarter 2024 earnings released: EPS: Rp90.00 (vs Rp126 in 1Q 2023)First quarter 2024 results: EPS: Rp90.00 (down from Rp126 in 1Q 2023). Revenue: Rp3.44t (up 6.4% from 1Q 2023). Net income: Rp407.4b (down 28% from 1Q 2023). Profit margin: 12% (down from 18% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 29Full year 2023 earnings released: EPS: Rp261 (vs Rp222 in FY 2022)Full year 2023 results: EPS: Rp261 (up from Rp222 in FY 2022). Revenue: Rp13t (up 7.1% from FY 2022). Net income: Rp1.18t (up 18% from FY 2022). Profit margin: 9.0% (up from 8.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Feb 21Now 21% undervaluedOver the last 90 days, the stock has risen 14% to Rp2,010. The fair value is estimated to be Rp2,541, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.2% over the last 3 years. Earnings per share has grown by 23%.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: Rp57.12 (vs Rp35.99 in 3Q 2022)Third quarter 2023 results: EPS: Rp57.12 (up from Rp35.99 in 3Q 2022). Revenue: Rp3.28t (up 4.2% from 3Q 2022). Net income: Rp259.3b (up 60% from 3Q 2022). Profit margin: 7.9% (up from 5.1% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: Rp27.67 (vs Rp24.01 in 2Q 2022)Second quarter 2023 results: EPS: Rp27.67 (up from Rp24.01 in 2Q 2022). Revenue: Rp3.25t (up 9.6% from 2Q 2022). Net income: Rp124.1b (up 14% from 2Q 2022). Profit margin: 3.8% (up from 3.6% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to Rp1,920, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 66% over the past three years.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to Rp1,785, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 62% over the past three years.Reported Earnings • Apr 30First quarter 2023 earnings released: EPS: Rp126 (vs Rp60.12 in 1Q 2022)First quarter 2023 results: EPS: Rp126 (up from Rp60.12 in 1Q 2022). Revenue: Rp3.23t (up 8.8% from 1Q 2022). Net income: Rp568.8b (up 110% from 1Q 2022). Profit margin: 18% (up from 9.1% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: No independent directors. 9 non-independent directors. Independent Commissioner Phillips Gunawan was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 10 non-independent directors. Independent Commissioner - Kustantinah was the last independent director to join the board, commencing their role in 2012. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 05Full year 2021 earnings releasedFull year 2021 results: EPS: Rp183. Revenue: Rp11t (up 2.4% from FY 2020). Net income: Rp823.8b (up 4.6% from FY 2020). Profit margin: 7.3% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 05Second quarter 2021 earnings released: EPS Rp27.23 (vs Rp19.26 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: Rp2.74t (up 5.9% from 2Q 2020). Net income: Rp122.5b (up 41% from 2Q 2020). Profit margin: 4.5% (up from 3.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jan 18Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to Rp1,650, the stock is trading at a trailing P/E ratio of 11.8x, down from the previous P/E ratio of 14.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 8.4%.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 40% share price gain to Rp1,990, the stock is trading at a trailing P/E ratio of 14.2x, up from the previous P/E ratio of 10.1x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 27%.Is New 90 Day High Low • Jan 07New 90-day high: Rp1,565The company is up 23% from its price of Rp1,275 on 09 October 2020. The Indonesian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.Valuation Update With 7 Day Price Move • Dec 09Market bids up stock over the past weekAfter last week's 18% share price gain to Rp1,540, the stock is trading at a trailing P/E ratio of 11x, up from the previous P/E ratio of 9.3x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years were flat.Is New 90 Day High Low • Dec 08New 90-day high: Rp1,390The company is up 7.0% from its price of Rp1,295 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.Reported Earnings • Nov 04Third quarter 2020 earnings released: EPS Rp27.64The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: Rp2.74t (down 2.7% from 3Q 2019). Net income: Rp124.9b (up 46% from 3Q 2019). Profit margin: 4.6% (up from 3.0% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Tempo Scan Pacific は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測IDX:TSPC - アナリストの将来予測と過去の財務データ ( )IDR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202614,143,0621,349,3211,151,9861,663,909N/A12/31/202514,005,0281,406,764866,3501,417,556N/A9/30/202513,638,0761,501,3261,198,5911,707,842N/A6/30/202513,476,2631,328,870899,6501,331,832N/A3/31/202513,488,0291,449,538903,1741,309,384N/A12/31/202413,654,5711,447,7251,321,5951,714,658N/A9/30/202413,503,6821,307,9591,110,8921,490,325N/A6/30/202413,410,1111,305,6421,197,9341,602,537N/A3/31/202413,327,8501,016,1031,122,8361,514,891N/A12/31/202313,119,7851,177,432872,8081,199,459N/A9/30/202312,930,9781,413,211565,610895,393N/A6/30/202312,799,6161,315,609247,553577,461N/A3/31/202312,515,6281,299,873-126,846382,383N/A12/31/202212,254,3691,001,628-106,328485,838N/A9/30/202211,979,281818,701-75,326515,620N/A6/30/202211,690,793793,249210,316758,437N/A3/31/202211,463,255807,365329,520696,162N/A12/31/202111,234,443823,768303,783689,653N/A9/30/202111,221,801837,814469,654912,298N/A6/30/202111,098,709826,410303,071762,923N/A3/31/202110,946,622790,636526,6661,020,773N/A12/31/202010,968,402787,803534,862982,699N/A9/30/202010,913,436633,438771,1211,179,750N/A6/30/202010,988,140594,286644,7881,041,704N/A3/31/202011,054,774635,033607,779979,217N/A12/31/201910,993,842554,263N/A889,775N/A9/30/201910,838,260506,498N/A619,486N/A6/30/201910,645,094503,850N/A408,176N/A3/31/201910,409,876511,785N/A441,738N/A12/31/201810,088,119512,029N/A389,088N/A9/30/20189,953,788524,501N/A376,158N/A6/30/20189,771,237544,322N/A506,230N/A3/31/20189,605,084539,972N/A515,125N/A12/31/20179,565,462543,804N/A544,164N/A9/30/20179,367,620518,924N/A578,985N/A6/30/20179,048,306534,918N/A681,287N/A3/31/20179,282,651537,987N/A535,662N/A12/31/20169,138,239536,274N/A491,655N/A9/30/20168,974,716461,111N/A541,774N/A6/30/20168,863,164488,536N/A370,625N/A3/31/20168,440,155495,765N/A523,417N/A12/31/20158,181,482521,959N/A778,362N/A9/30/20158,042,806551,874N/A590,071N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: TSPCの予測収益成長が 貯蓄率 ( 6.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: TSPCの収益がID市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: TSPCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: TSPCの収益がID市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: TSPCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: TSPCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/11 21:49終値2026/07/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PT Tempo Scan Pacific Tbk 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Selviana AripinHSBCHarry SuPT Bahana Securities
お知らせ • May 14PT Tempo Scan Pacific Tbk, Annual General Meeting, Jun 05, 2026PT Tempo Scan Pacific Tbk, Annual General Meeting, Jun 05, 2026. Location: tempo scan tower, lt.16, jl. h. r. rasuna said kav, jakarta selatan kota adm. jakarta selatan dki., . jakarta indonesia, jakarta Indonesia
Reported Earnings • May 05First quarter 2026 earnings released: EPS: Rp78.00 (vs Rp91.00 in 1Q 2025)First quarter 2026 results: EPS: Rp78.00 (down from Rp91.00 in 1Q 2025). Revenue: Rp3.41t (up 4.2% from 1Q 2025). Net income: Rp351.8b (down 14% from 1Q 2025). Profit margin: 10% (down from 13% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 01Full year 2025 earnings released: EPS: Rp312 (vs Rp321 in FY 2024)Full year 2025 results: EPS: Rp312 (down from Rp321 in FY 2024). Revenue: Rp14t (up 2.6% from FY 2024). Net income: Rp1.41t (down 2.8% from FY 2024). Profit margin: 10.0% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 04Third quarter 2025 earnings released: EPS: Rp95.94 (vs Rp58.00 in 3Q 2024)Third quarter 2025 results: EPS: Rp95.94 (up from Rp58.00 in 3Q 2024). Revenue: Rp3.54t (up 4.8% from 3Q 2024). Net income: Rp434.1b (up 66% from 3Q 2024). Profit margin: 12% (up from 7.8% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Nov 03Upcoming dividend of Rp100.00 per shareEligible shareholders must have bought the stock before 10 November 2025. Payment date: 25 November 2025. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Indonesian dividend payers (5.3%). Higher than average of industry peers (2.8%).
Board Change • Oct 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 10 non-independent directors. Independent Commissioner Suparni Setiono was the last independent director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 16PT Tempo Scan Pacific Tbk, Annual General Meeting, May 23, 2025PT Tempo Scan Pacific Tbk, Annual General Meeting, May 23, 2025. Location: meeting both physically and eletronically, jakarta Indonesia
Reported Earnings • Nov 01Third quarter 2024 earnings released: EPS: Rp58.00 (vs Rp57.12 in 3Q 2023)Third quarter 2024 results: EPS: Rp58.00 (up from Rp57.12 in 3Q 2023). Revenue: Rp3.37t (up 2.9% from 3Q 2023). Net income: Rp261.7b (flat on 3Q 2023). Profit margin: 7.8% (down from 7.9% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.
Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to Rp2,800, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 135% over the past three years.
Reported Earnings • Aug 01Second quarter 2024 earnings released: EPS: Rp92.01 (vs Rp27.67 in 2Q 2023)Second quarter 2024 results: EPS: Rp92.01 (up from Rp27.67 in 2Q 2023). Revenue: Rp3.34t (up 2.5% from 2Q 2023). Net income: Rp413.6b (up 233% from 2Q 2023). Profit margin: 12% (up from 3.8% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 16% per year.
Buy Or Sell Opportunity • May 21Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at Rp2,020. The fair value is estimated to be Rp2,541, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 18%.
Reported Earnings • May 02First quarter 2024 earnings released: EPS: Rp90.00 (vs Rp126 in 1Q 2023)First quarter 2024 results: EPS: Rp90.00 (down from Rp126 in 1Q 2023). Revenue: Rp3.44t (up 6.4% from 1Q 2023). Net income: Rp407.4b (down 28% from 1Q 2023). Profit margin: 12% (down from 18% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 29Full year 2023 earnings released: EPS: Rp261 (vs Rp222 in FY 2022)Full year 2023 results: EPS: Rp261 (up from Rp222 in FY 2022). Revenue: Rp13t (up 7.1% from FY 2022). Net income: Rp1.18t (up 18% from FY 2022). Profit margin: 9.0% (up from 8.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Feb 21Now 21% undervaluedOver the last 90 days, the stock has risen 14% to Rp2,010. The fair value is estimated to be Rp2,541, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.2% over the last 3 years. Earnings per share has grown by 23%.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: Rp57.12 (vs Rp35.99 in 3Q 2022)Third quarter 2023 results: EPS: Rp57.12 (up from Rp35.99 in 3Q 2022). Revenue: Rp3.28t (up 4.2% from 3Q 2022). Net income: Rp259.3b (up 60% from 3Q 2022). Profit margin: 7.9% (up from 5.1% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: Rp27.67 (vs Rp24.01 in 2Q 2022)Second quarter 2023 results: EPS: Rp27.67 (up from Rp24.01 in 2Q 2022). Revenue: Rp3.25t (up 9.6% from 2Q 2022). Net income: Rp124.1b (up 14% from 2Q 2022). Profit margin: 3.8% (up from 3.6% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to Rp1,920, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 66% over the past three years.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to Rp1,785, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 62% over the past three years.
Reported Earnings • Apr 30First quarter 2023 earnings released: EPS: Rp126 (vs Rp60.12 in 1Q 2022)First quarter 2023 results: EPS: Rp126 (up from Rp60.12 in 1Q 2022). Revenue: Rp3.23t (up 8.8% from 1Q 2022). Net income: Rp568.8b (up 110% from 1Q 2022). Profit margin: 18% (up from 9.1% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: No independent directors. 9 non-independent directors. Independent Commissioner Phillips Gunawan was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 10 non-independent directors. Independent Commissioner - Kustantinah was the last independent director to join the board, commencing their role in 2012. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 05Full year 2021 earnings releasedFull year 2021 results: EPS: Rp183. Revenue: Rp11t (up 2.4% from FY 2020). Net income: Rp823.8b (up 4.6% from FY 2020). Profit margin: 7.3% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 05Second quarter 2021 earnings released: EPS Rp27.23 (vs Rp19.26 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: Rp2.74t (up 5.9% from 2Q 2020). Net income: Rp122.5b (up 41% from 2Q 2020). Profit margin: 4.5% (up from 3.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jan 18Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to Rp1,650, the stock is trading at a trailing P/E ratio of 11.8x, down from the previous P/E ratio of 14.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 8.4%.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 40% share price gain to Rp1,990, the stock is trading at a trailing P/E ratio of 14.2x, up from the previous P/E ratio of 10.1x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 27%.
Is New 90 Day High Low • Jan 07New 90-day high: Rp1,565The company is up 23% from its price of Rp1,275 on 09 October 2020. The Indonesian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 09Market bids up stock over the past weekAfter last week's 18% share price gain to Rp1,540, the stock is trading at a trailing P/E ratio of 11x, up from the previous P/E ratio of 9.3x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years were flat.
Is New 90 Day High Low • Dec 08New 90-day high: Rp1,390The company is up 7.0% from its price of Rp1,295 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
Reported Earnings • Nov 04Third quarter 2020 earnings released: EPS Rp27.64The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: Rp2.74t (down 2.7% from 3Q 2019). Net income: Rp124.9b (up 46% from 3Q 2019). Profit margin: 4.6% (up from 3.0% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.